CTLA4 and neoplasm: Anti-CTLA-4 mAbs with the same Fc variants employed in ipilimumab (IgG1) and tremelimumab (IgG2) both induced in vivo depletion of tumor-infiltrating Treg cells in the context of human FcγRs.